Chondrex: New marker of joint disease

Sheryl Harvey, Michael Weisman, James O'Dell, Tonya Scott, Mindy Krusemeier, Jill Visor, Cathy Swindlehurst

Research output: Contribution to journalArticle

141 Scopus citations

Abstract

Chondrex, a major secretory protein of human chondrocytes and synovial fibroblasts, is increased in serum of patients with joint and cartilage disease. We have developed a sandwich-type ELISA for quantifying chondrex in serum. The interassay CVs were 2.8-3.7% and the average within-run and total CVs were 3.6% and 5.4%, respectively. The limit of detectability by linear dilution was 20 μg/L, recovery upon dilution was 102% ± 5%, and analytical recovery (of added analyte) was 98% ± 11%. The reference interval (central 90% interval) for chondrex in healthy adults was 25-95 μg/L. Chondrex values for patients with active rheumatoid arthritis or osteoarthritis were significantly greater than in healthy adults, inactive rheumatoid arthritis patients, and diabetes patients (P <0.05). In patients treated with disease- modifying antirheumatic drug therapy, decreasing chondrex values reflected the clinical improvement observed in responders, whereas the values were maintained or increased in nonresponders. In conclusion, chondrex may be a useful marker in the clinical investigation of arthritis.

Original languageEnglish (US)
Pages (from-to)509-516
Number of pages8
JournalClinical Chemistry
Volume44
Issue number3
DOIs
StatePublished - 1998

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical

Fingerprint Dive into the research topics of 'Chondrex: New marker of joint disease'. Together they form a unique fingerprint.

  • Cite this

    Harvey, S., Weisman, M., O'Dell, J., Scott, T., Krusemeier, M., Visor, J., & Swindlehurst, C. (1998). Chondrex: New marker of joint disease. Clinical Chemistry, 44(3), 509-516. https://doi.org/10.1093/clinchem/44.3.509